Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.55 USD

76.55
859,950

+1.47 (1.96%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $76.58 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips

Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.

Haemonetics (HAE) Q4 Earnings and Revenues Miss Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of -31.34% and -0.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) to Report Q4 Earnings: What's in the Cards?

Continued benefits from the NexSys device and NexLynk DMS along with robust TEG devices sales are expected to have contributed to Haemonetics (HAE) fourth-quarter top line.

Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays

Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.

Reasons to Hold on to Syneos Health (SYNH) Stock For Now

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.

Here's Why You Should Add Haemonetics (HAE) to Your Portfolio

Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.

Haemonetics (HAE) Down 5.8% Since Last Earnings Report: Can It Rebound?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts

Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.

Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 19.12% and 6.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stock Earnings on Feb 2: IDXX, MCK & More

In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.

PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?

PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at Diagnostics segment.

McKesson (MCK) to Report Q3 Earnings: What's in the Offing?

McKesson's (MCK) fiscal third-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

Haemonetics (HAE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABIOMED (ABMD) to Report Q3 Earnings: What's in the Cards?

The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Varian (VAR) to Report Q1 Earnings: What's in the Offing?

Varian's (VAR) fiscal first-quarter earnings are likely to reflect strength in Halcyon platform.

Haemonetics (HAE) Hits New 52-Week High: What's Driving It?

Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?

Intuitive Surgical's (ISRG) fourth-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.

Haemonetics (HAE) Up 14.6% Since Last Earnings Report: Can It Continue?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Haemonetics (HAE) New Products Aid, Plasma Sales Remain Tepid

Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 24.00% and 3.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?